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Abstract
Background: Clinical trials evaluating the use of hypertonic saline in the treatment of hypovolemia
and head trauma suggest no survival superiority over normal saline; however subgroup analyses
suggest there may be a reduction in the inflammatory response and multiorgan failure which may
lead to better survival and enhanced neurocognitive function. We describe a feasibility study of
randomizing head injured patients to hypertonic saline and dextran vs. normal saline administration
in the out of hospital setting.
Methods/Design:  This feasibility study employs a randomized, placebo-controlled design
evaluating normal saline compared with a single dose of 250 ml of 7.5% hypertonic saline in 6%
dextran 70 in the management of traumatic brain injuries. The primary feasibility endpoints of the
trial were: 1) baseline survival rates for the treatment and control group to aid in the design of a
definitive multicentre trial, 2) randomization compliance rate, 3) ease of protocol implementation
in the out-of-hospital setting, and 4) adverse event rate of HSD infusion.
The secondary objectives include measuring the effect of HSD in modulating the immuno-
inflammatory response to severe head injury and its effect on modulating the release of neuro-
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biomarkers into serum; evaluating the role of serum neuro-biomarkers in predicting patient
outcome and clinical response to HSD intervention; evaluating effects of HSD on brain atrophy
post-injury and neurocognitive and neuropsychological outcomes.
Discussion: We anticipate three aspects of the trial will present challenges to trial success; ethical
demands associated with a waiver of consent trial, challenging follow up and comprehensive
accurate timely data collection of patient identifiers and clinical or laboratory values. In addition all
the data collection tools had to be derived de novo as none existed in the literature.
Trial registration number: NCT00878631
Background
Hypertonic Saline provides an alternative to large volume
time limited resuscitation to restore hemodynamic stabil-
ity and minimize the posttraumatic organ dysfunction.
There is however, no clear clinical evidence supporting the
hypothesis that hypertonic saline is the optimal choice for
prehospital trauma resuscitation, specifically with respect
to brain injury. Most of the current evidence demonstrat-
ing anti-inflammatory and immunological properties of
hypertonic saline comes from experimental models (ani-
mal and isolated cell preparations) and remains untested
in humans. A recent meta-analysis demonstrated that
hypotensive patients with severe head injury are twice as
likely to survive if resuscitated with hypertonic saline in
dextran (HSD) compared with isotonic crystalloids [1] In
separate clinical trials, HSD resuscitation was associated
with a reduced incidence of acute respiratory distress syn-
drome (ARDS), renal failure and infectious complications
[2-4]. Because of the compelling current evidence suggest-
ing the effectiveness of HSD and the known burden of
traumatic brain injury (TBI) and multiorgan dysfunction,
this question requires direct evaluation.
The application of rigorous clinical trial methodology in
the prehospital setting requires overcoming a number of
challenges unique to the setting. We conducted a feasibil-
ity study prior to implementing a larger randomized clin-
ical efficacy trial. This feasibility study is significantly
different from other prehospital trauma trials because it is
designed by investigators from multiple disciplines
including immunology, neurology, surgery, anaesthesia,
neuropsychology and neuroimaging to address aspects of
TBI not evaluated previously and employs a randomized
clinical trial design and waiver of consent. In addition to
the primary study objective of survival at 30 days we plan
to evaluate circulating and cellular immunomodulation
within the first 24 hours, neurocognitive and neuropsy-
chological testing at 4 and 12 months, and structural dam-
age through MRI scanning up to 4 months post trauma.
We report the methods in detail and have appended the
data collection tools and case report forms for this feasi-
bility study. All case report forms and data collection
forms were created by the investigators as prior forms did
not exist previously in the literature.
Methods/Design
Study design
The Toronto Prehospital Hypertonic Resuscitation-Head
Injury and Multi Organ Dysfunction Trial (TOPHR HIT) is
a randomized, placebo-controlled trial of blunt trauma
patients with head injuries. The study compares a group
receiving normal saline according to a paramedic's proto-
col, with a treatment group receiving a single dose 250 ml
of 7.5% hypertonic saline in 6% dextran 70 (RescueFlow®
BioPhausia AB, Stockholm Sweden). The study was
approved by the Canadian Therapeutic Products Directo-
rate Control Number 092523 and registered at http://
www.clinical.trials.gov. Inclusion and exclusion criteria
are summarized in Additional file 1.
Study Objective
The primary objective of this study is to report feasibility
in accordance with the methodology described by Lancas-
ter and Dodds [5], specifically addressing:
1) baseline survival rates for the treatment and control
group to aid in the design of a definitive multicentre
trial;
2) randomization compliance rate;
3) ease of protocol implementation in the out-of-hos-
pital setting;
4) adverse event rate of HSD infusion.
The secondary objectives include measuring the effect of
HSD in modulating the immuno-inflammatory response
to severe head injury and its effect on modulating the
release of neuro-biomarkers into serum; evaluating the
role of serum neuro-biomarkers in predicting patient out-
come and clinical response to HSD intervention; and eval-
uating effects of HSD on brain atrophy post-injury and
neurocognitive and neuropsychological outcomes.Trials 2009, 10:105 http://www.trialsjournal.com/content/10/1/105
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Randomization
The study employs a block randomization by station
derived from a computer-generated random number
table. Blocks of two study packages are assigned to each
ambulance vehicle/aircraft. Paramedics are blinded to the
treatment assigned until package opening. A field logistics
research coordinator is responsible for randomization
compliance at the vehicle level through daily checks.
Compliance at the patient will be verified through the ran-
domization number of the product label and recorded on
the data checklist.
Setting
The trial setting is the city of Toronto with a population of
at 2.5 million served by an emergency medical services
system employing approximately 430 Advanced Life Sup-
port Paramedics, 570 Basic Life Support Paramedics and
3,000 Firefighter first responders under the same medical
direction. In addition, the trial includes one Ornge Trans-
port Medicine rotor wing base with two helicopters and
32 critical care flight paramedics providing responses
from accident scenes outside the city of Toronto within
south central Ontario. Enrolled patients will be directly
admitted to two adult designated regional Trauma Cent-
ers.
Intervention Protocol
All patients will be treated according to research medical
directives (Additional File 2) based on a standardized pro-
vincial out of hospital trauma treatment protocol [6]. The
study solution is started within 4 hours of the time the
emergency call was received at ambulance dispatch. Sam-
ples of peripheral blood will be collected upon emergency
department (ED) arrival, 12, 24 and 48 hours after ED
arrival from a vein remote from the venous access site for
the study infusion. Blood samples will be collected in
heparinized and non-additive vacutainers by a single
trained lab technician and immediately (within 1-h)
shipped to a single designated laboratory for whole blood
flow cytometric cellular analyses and measurement of cir-
culating molecular immuno-inflammatory markers.
Serum will be frozen for subsequent analyses. Whole
blood will be incubated with saturating concentrations of
the adhesion (CD62L-FITC, CD11b-PE), degranulation
(CD66b-FITC, CD63-PE), apoptotic/necrotic (Annexin V-
PE, 7-AAD, Active Caspase-3, CD95-Fas, CD178-FasL)
markers, in conjunction with CD14-APC surface staining
(to differentiate leukocyte subsets). Results will be
acquired on a Becton Dickinson dual-laser (488 nm and
635 nm) BD FACSCalibur flow cytometer using CellQuest
software. Serum samples will be analyzed for pro-/anti-
inflammatory cytokines (TNF-α, IL-10), soluble leukocyte
and endothelial-derived adhesion molecules (sICAM-1,
sVCAM-1, sE-selectin, sL-selectin), pro-/anti-apoptotic
molecules (sCD95, sCD95L, TNF-RI, sFas/FasL) and
neuro-biomarkers of brain injury (S100B, NSE, MBP)
(Additional File 3).
Magnetic Resonance Imaging on a 1.5 Tesla General Elec-
tric Signa Magnet is planned for completion at 4 months
for consenting patients using a standardized protocol
(Additional File 4, 5, 6, 7); a 3D 1.3 mm thick, T1-
weighted, series (TE 4-2, TR 35, flip angle 35), an inter-
leaved 3 mm thick PD and T2-weighted spin echo
sequence (TE 39/80, TR 3000, flip angle 90) (Additional
File 6), a gradient echo sequence and Diffusion Tensor
Imaging (11 directions) (Additional File 7); tissue seg-
mentation and parcellation including lesion quantifica-
tion [7-12] using previously published in-house software
as well as ANALYZE software [7,13].
Study outcomes
Survival
The primary clinical outcome is survival at 30 days.
Secondary clinical outcomes are survival at 48 hours and
to hospital discharge.
Neurocognitive Outcomes
At discharge:
￿ Cerebral Performance Category [14]
At 4 months:
￿ Functional Independence Measure (FIM)[15]
￿ Disability Rating Scale (DRS) [16-19]
￿ Glasgow Outcome Scale (GOS)[16,20,21]
￿ Glasgow Outcome Scale Extended (GOS
Extended)[16,20]
Neuropsychological Outcomes
At 4 months:
￿ Learning and Memory
❍California Verbal Learning Test[22]
❍Wechsler Memory Scale-Revised Immediate and
Delayed Visual Reproduction[23]
❍Rey-Osterreith Immediate and Delayed Mem-
ory[24]
￿ Working Memory
❍WMS-R Backward Digit Span[23]Trials 2009, 10:105 http://www.trialsjournal.com/content/10/1/105
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￿ Executive Function
❍FAS Verbal Fluency[25]
❍Wisconsin Card Sorting Test[26]
❍Trail Making Test Parts A & B[27]]
❍Stroop Test[28]
❍Object Alternation[29]
❍WMS-R Forward Digit Span[23]
￿ Language Function
❍Boston Naming Test[27]
❍Semantic Fluency[25]
￿ Visuospatial Function
❍Judgment of Line Orientation[30]
❍Facial Recognition[30]
￿ Speed of Processing
❍WAIS-R Digit Symbol[31]
❍Trail Making Test Part A[27]
￿ Beck Depression Scale[32].
A focused attention reaction time test[33,34] with varying
levels of complexity will be administered at 12 months.
Structural Outcomes
The structural brain parameters will be evaluated by MRI
as described above [7-10] (Additional File 4, 5, 6, 7) and
will be measured by a published protocol [8] (Additional
File 8, 9). This includes evaluation of:
￿ Total brain volume and regional volumes (frontal
anterior and medial temporal) and medial temporal
to be the width [8] (Proton Density T2T1-Weighted)
[7]
￿ Fractional Anistropy (Diffusion Tensor Imaging)
￿ N-acetyl-aspartate/creatinine ratio (Proton magnetic
resonance spectroscopy) [9,10]
￿ Haemosiderin deposits on gradient echo MRI
￿ Serum S100B astrocytosis marker of brain injury and
C Reactive Protein [35]
Cellular and Molecular Biomarkers
Whole blood and circulating immuno-inflammatory
markers will be measured on hospital arrival and at 12, 24
and 48 hours later
￿ Total leukocyte count and differential; neutrophil
and monocyte surface expression of cellular adhesion
molecules and degranulation markers: L-selectin
(CD62L) and β2-integrin (CD11b) [36]
￿ Leukocyte apoptotic/necrotic surface and intracellu-
lar markers (Annexin V-PE, 7-AAD, Active Caspase-3,
Fas (CD95), FasL (CD178) [37-42]
￿ Soluble pro-/anti-apoptotic molecules (sCD95,
sCD95L, TNF-RI, sFas/FasL)[43]
￿ Leukocyte and endothelial-derived serum soluble
adhesion molecule concentrations: intercellular adhe-
sion molecule-1 (sICAM-1), vascular adhesion mole-
cule-1 (sVCAM-1), sE-selectin, sL-selectin [44-46]
￿ Pro and anti-inflammatory cytokine expression:
tumour necrosis factor (TNF)-α, and interleukin (IL)-
10 [37,47,48];
￿ PT/PTT, tissue factor (TF), thrombomodulin (TM),
fibrinogen, platelet count and Hg; Ionized calcium,
and pH [49]
￿ Serum sodium, chloride and osmolarity
Safety and Dependability
The Paramedic Data Checklist (Additional File 10) and
both the land and air prehospital (Additional File 11&12)
and inhospital (Additional File 13) Case Report Forms
explicitly ask whether or not adverse drug reactions with a
definite causal relationship to the HSD have occurred.
These adverse drug reactions will be predetermined by the
Steering Committee based on the literature where possi-
ble. (Table 1) The Steering Committee will validate all
outcomes and determined adverse events blinded to treat-
ment assignment. This feasibility trial is approved by the
Institutional Research Ethics Board.
Data Management
Paramedics complete a data checklist (Additional File 10)
and standardized provincial patient care record. A single
paramedic data abstractor will abstract data from the par-
amedic checklist and patient care record onto a prehospi-
tal case report form (Additional File 11). Site specificTrials 2009, 10:105 http://www.trialsjournal.com/content/10/1/105
Page 5 of 9
(page number not for citation purposes)
inhospital research staff will abstract data from the
patient's chart daily and completed an inhospital case
report form (Additional File 13). In-hospital patient data
includes the interpretation of head CT scans employing
the Marshall Classification system [50] as well as the
Injury Severity Score [51]. Measures of organ dysfunction:
Acute Physiologic and Chronic Health Evaluation
(APACHE II)[52,53], Sequential Organ Failure Assess-
ment (SOFA) [54] and Multiple Organ Dysfunction Score
(MODS)[55] will be evaluated at ICU admission. In addi-
tion, SOFA and MODS will be recorded every other day
until ICU discharge. Data entry onto a web based (prehos-
pital data) or SAS version 8.0 interface (inhospital and fol-
low up data) will be performed by a single trained data
entry specialist.
Analysis Plan
This is a feasibility study of two year's duration with a pro-
jected screening of 130 patients and recruitment of 100.
The primary outcome measure, change in the proportion
surviving 30 days post trauma between the treatment and
control groups, will be analyzed by means of a generalized
linear mixed model which included covariates of interest.
The two groups are not expected to be different at base-
line, and it is hypothesized that the treatment group
would show a 20% decrease in mortality at 30 days post
trauma whereas the control group would remain
unchanged. To derive a reduced subset of risk factors for
the predictor models, acceptable model building strate-
gies are planned (i.e. dropping variables showing
extremely small variability and those found to be highly
correlated (i.e. correlation coefficient ≥0.8)). Treatment
and time factors will be analyzed using a generalized lin-
ear mixed models of the secondary outcome repeated
measures: the change in mortality after discharge over
time as well as the neurocognitive and neuropsychologi-
cal outcome summary scores. For secondary outcome
analyses, the alpha will be adjusted to account for multi-
ple comparisons. Where there is more than one measure
for a neuropsychological test (e.g., processing speed,
working memory, visuospatial, language, verbal memory,
non-verbal memory - with the exception of executive
processes, since different measures relate to different brain
regions), a composite or prototypical measure will be
derived from group comparison. Serial changes in all sec-
ondary immune modulation measures, neuro-biomark-
Table 1: Adverse Event Definitions
Event Expected Unexpected
Brain Injury
(Serious)
Demyelination
Any text reference in imaging reports to 'Central 
Pontine Myelinosis or Pontine Hyperintensity' in any 
MRI report during hospital stay
Subarachnoid Hemmorhage
Any text reference in imaging reports of 
CT of MRI within 24 hours of arrival to 
Emergency Department to 
'Subarachnoid Hemmorhage or SAH' 
when the first CT scan was normal
Anaphylactoid Reaction
(Serious)
Any text reference in physician notes within the first 
24 hours of arrival to Emergency Department to 
'anaphylactoid reaction'
Prolonged Partial Thromboplastin Time
(Non serious)
Normal up to 40
May see up to 85 with HSD
> 100
International Normalized Ratio
(Non serious)
Normal up to 1.5
May see up to 3.0 with HSD
> 3.0
Serum Sodium
(Non serious)
Normal range 135-147
May see up to 158 with HSD
> 160
Serum Osmolarity
(Non serious)
Normal range 310-330
May see up to 350 with HSD without alcohol
> 350 without alcohols
Serum Chloride
(Non serious)
Normal range 96-108
May see up to 145
>150
Rouleau formation
(Non serious)
May be present
MRI Magnetic Resonance Imaging
CT Computerized Tomography Scan
SAH Subarachnoid HemmorhageTrials 2009, 10:105 http://www.trialsjournal.com/content/10/1/105
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ers, neurocognitive and neuropsychological outcomes,
and structural imaging measures will be evaluated by two-
way ANOVA for repeated measures. All analysis will be
conducted blinded to treatment assignment.
Ethical Considerations
We received waiver of consent approval in accordance
with the Tri-Council Policy Agreement http:www.pre.eth-
ics.gc.ca/english/policystatement/poli cystatement.cfm.
We will seek consent from the surviving patients or the
families of non survivors to analyze the blood results of
all randomized patients. An itemized consent will be used
where appropriate to record simultaneously consent for
all follow up tests and evaluation of surviving patients.
Discussion
The metaanalysis by Wade et al[1] suggested TBI was the
cohort of patients most likely to demonstrate significant
changes with HSD resuscitation. This study is designed to
test the feasibility of randomizing patient in the prehospi-
tal setting to this cohort of patients and explore through
additional tests, the important immunological, serum
markers, structural changes and neuropsychological and
neurocognitive outcomes in addition to the traditional
survival outcomes.
We anticipate three aspects of the trial will present chal-
lenges to trial success; ethical demands, challenging fol-
low up and comprehensive accurate timely data collection
of patient identifiers and clinical or laboratory values. The
ethical considerations are probably the most challenging
as we will have to secure consent to analyze the blood of
non survivors from families who have suffered an unex-
pected and devastating loss through trauma.
Additionally, we are concerned that many patients will be
lost to follow up as individuals who survive TBI may be
unable to return to their previous address or place of occu-
pation and are very dependent on family. If important
links to the family are not established during the first hos-
pitalization and maintained post discharge we may be
unable to find all the patients. In addition, the structural
and neurocognitive and neuro psychological tests require
a return visit to hospital. This may place additional
demands on the family and care giver who may be over-
whelmed given the functionality of some traumatic brain
patients.
Finally, we anticipate two types of patients will provide
unique challenges to data collection: those who die in the
Emergency Department and those who met the Glasgow
Coma Scale criteria for enrolment however this finding
was attributed to drugs or alcohol rather than brain injury
and they were discharged from the Emergency Depart-
ment within hours of the accident. Strategies are in place
to address these issues a priori in advance of the trial.
Those who die soon after arrival in the Emergency Depart-
ment often require the coroner's intervention and tradi-
tionally the charts are instantly sequestered by the
coroner's staff. They commonly are unidentified and
therefore it will be hard to find their health care advocate
who can consent to using their blood and outcome data
up until their death. We hope to overcome this with an
agreement in principle with the provincial coroner to
allow access to the chart at the coroner's office. We have
developed a working practice with the coroner's office to
confirm identification and next of kin data at the time of
body retrieval
We anticipate the patients who met the GCS eligibility cri-
teria based on alcohol consumption and are discharged
relatively quickly from the Emergency Department will be
hard to track down. There will be insufficient time to iden-
tify them correctly or confirm their demographic informa-
tion and next of kin prior to discharge and follow up of
the non brain injured group will be challenging. We will
use a hierarchical approach to find these patients includ-
ing government health care billing number, police report,
Emergency Department report, Ambulance call report,
web based telephone listings, newspapers which identify
the individual based on the notoriety of the event. In
addition, each receiving hospital had an active trauma reg-
istry which tracked the patients to conduct a functional
evaluation at 30 days post-discharge. The surgical investi-
gators have offered to confirm identification and obtain
consent in their outpatient clinics if the patients return for
follow up. This may prove to be helpful as many of these
patients require forms completed by the physician for
return to work, disability, insurance etc.
This study incorporates several unique features which may
be helpful to subsequent trials. It is a feasibility design
that follows a rigorous published methodology. It evalu-
ates the feasibility of the out of hospital randomization as
well as the inhospital data capture and analysis of compli-
cated critical care variables, immunological markers, CT
and MRI studies, and neurocognitive evaluation. The data
capture forms appended to this document had to be cre-
ated by the investigators as none could be found in the lit-
erature despite numerous studies in a similar cohort of
patients. This should save others time and permit a more
standardized data capture for future trials should they
prove useful when reviewed by our peers. We hope pro-
viding the methodology will encourage others to test the
feasibility of a randomized controlled trial before imple-
mentation in the complicated and costly out of hospital
arena.Trials 2009, 10:105 http://www.trialsjournal.com/content/10/1/105
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Abbreviations
ICU: Intensive Care Unit; CT: Computerized Tomogra-
phy; MRI: Magnetic Resonance Imaging; All other short
forms are written in full with first use.
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